BUSINESS

Takeda Pitches In Production Capacities for J&J’s COVID-19 Vaccine

March 17, 2021
Takeda Pharmaceutical is offering its production capacities at a German contract manufacturer previously reserved for its approval-pending dengue vaccine for Johnson & Johnson to churn out its single-dose COVID-19 vaccine shots. In their separate statements dated on March 15, Takeda…

To read the full story

BUSINESS

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Tatsuya Otsuka

The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…